Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified new tricyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Shanghai Apeiron Biotechnology Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Researchers at Guangzhou Salustier Biosciences Co. Ltd. and Jinan University (Guangdong) have identified selenium-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Ensem Therapeutics Inc. has disclosed quinazoline derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Gilead Sciences Inc. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Hyperway Pharmaceutical Co. Ltd. and Shenzhen Hyperway Pharmaceuticals Co. Ltd. have disclosed new GTPase KRAS (G12D mutant) inhibitors.

Suzhou Zelgen Biosciences Co. Ltd. has synthesized GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of pancreatic cancer.

Bayer AG has identified fused pyrimidines GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Medshine Discovery Inc. has divulged GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.